Breast Cancer Product Details

Apatinib Mesylate Tablets

Model: Manufacturer
|
Category: Other

JIANGSU HENGRUI MEDICINE CO.,LTD

Quick Info

This product is suitable for patients with advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma who have progressed or relapsed after at least 2 systemic chemotherapy treatments. Patients should be in good general condition during treatment.

Description
Specification Features
Dosage Administration
Faqs

[Ingredients]
The main ingredient of this product is apatinib mesylate
Chemical name: N-[4-(1-cyanocyclopentyl) phenyl]-2-(4-pyridylmethyl)amino-3-pyridinecarboxamide methanesulfonate
Chemical structure:
Molecular formula: C24H23N5O·CH4SO3

[Indications] This product is suitable for patients with advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma who have progressed or relapsed after at least 2 systemic chemotherapy treatments. Patients should be in good general condition during treatment.

Calculated as apatinib (C24H23N5O): (1) 0.425 g; (2) 0.375 g; (3) 0.25 g.

[Usage and Dosage] This product should be used under the guidance of an experienced doctor.

Recommended dose: 850 mg, once a day.

Dosage: Oral, half an hour after a meal (the time of daily medication should be as consistent as possible), with warm water. The dose of apatinib missed during the course of treatment cannot be supplemented. Treatment duration: Continuous use until disease progression or intolerable adverse reactions occur.

[Contraindications] This product should not be used by patients who are allergic to any of its ingredients; it should not be used by patients with active bleeding, ulcers, intestinal perforation, intestinal obstruction, within 30 days after major surgery, hypertension that cannot be controlled by drugs, grade III-IV heart failure (NYHA standard), and severe liver and kidney failure (grade 4).

×